Loading
A phase 2 trial of Laser interstitial thermal therapy systems in Glioma & glioblastoma, run by University of Florida, now recruiting.
OPTIMUS PRIME: Safety and Feasibility of OPTune GIO® Integrated With MRI-gUided Laser Ablation Surgery and Pembrolizumab for Recurrent GlIoblastoMa, A randomizEd Trial is a phase 2 interventional study registered as NCT06558214 by University of Florida, with 20 participants planned, started 2024-12-10 and due to reach its primary completion in 2029-10. Interventions recorded: Pembrolizumab, Optune GIO®, NeuroBlate®. Conditions recorded: Recurrent Glioblastoma.
Linked to the technology Laser interstitial thermal therapy systems because the registry names it ("neuroblate") among its interventions and Glioma & glioblastoma among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Laser interstitial thermal therapy systems (NeuroBlate, Visualase), Glioma & glioblastoma and the tag pipeline.
Shares Laser interstitial thermal therapy systems (NeuroBlate, Visualase) and the tag pipeline.
Shares Glioma & glioblastoma, Pembrolizumab and the tag pipeline.
Shares Glioma & glioblastoma, Pembrolizumab and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/